Repair Biotechnologies’ presentation in favor of its drug ‘REP-0003’

Announcement

Repair Biotechnologies Inc. highlighted its current presentation of preclinical data proving the regression and potential of atherosclerotic plaque with REP-0003 treatment under its preclinical data at the American Heart Association’s (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, held from 7^th to 10^th November 2025. The REP-0003 drug was promoted as a proven excellent drug with safety and efficacy, ensuring the mitigation developed atherosclerotic plaque.

Repair Biotechnologies describing REP-0003 therapy

Repair Biotechnologies establishes that the REP-0003 therapy is stood on the exclusive Cholesterol Degrading Platform (CDP). The platform has the potential to safely break down the existing undruggable focus of massive free cholesterol inside the cells. The excess free cholesterol is hazardous to cells and supports the development of various issues with high unmet medical needs.

Basically, this involves the leveraged growth of atherosclerotic lesions that drives the patient group with homozygous familial hypercholesterolemia (HoFH). The developed therapies mitigating LDL-cholesterol in the bloodstream serve average or low improvement on this intracellular free cholesterol.

Impressive poster by Repair Biotechnologies

The poster presentation title is ‘Selective Degradation of Excess Free Cholesterol in the Liver by REP-0003 Regresses Atherosclerotic Plaque in Ldlr-/- Mice: A Novel Approach for HoFH’. The poster presentation was showcased in a moderated digital poster session by Dr Topors on 9^th November 2025. The AHA’s Scientific Sessions amazed the individuals present in the room, as the session is known for its popular yearly gathering in cardiovascular medicine and research.

The session involves multiple experts from 100 different deserving nations to share and learn about the breakthrough discoveries revolving around 21 disciplines. Highlighting research here provides exponential value to organisations, scientists and medical practitioners, offering a prestigious platform for framing advancements and sharing innovative insights in the domain. The session empowers many great minds to discover excellence in the healthcare sector.

Chief Scientific Officer of Repair Biotechnologies, Dr Mourad Topors, said, “Our latest presented preclinical data elaborates continuous and safe regression of developed atherosclerotic plaque in the Lldr-/- mice model involving treatment for six weeks with REP-0003. The safety profile and excellent results underscore our trust in the utility of major clearance of intracellular free cholesterol as a capable treatment for HoFH.”

Topors added, “We have been empowered by the increased interest in this existing undruggable focus following our achievement of Orphan Drug Designation in May this year by the US Food and Drug Administration for HoFH treatment.”